Nivolumab Plus Ipilimumab in Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma

According to a study, patients with intermediate- or poor-risk disease, median overall survival was not estimable in the nivolumab/ipilimumab group vs 25.9 months in the sunitinib arm (hazard ratio [HR] = 0.63, P
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news